Skip to content

600538.SH

Beihai Gofar Chuanshan Biological Co., Ltd.

SSE · Healthcare · Medical - Pharmaceuticals · CN

CNY 5.13
−1.54%
Ask drillr

Year over year

Reported trailing growth

Revenue
+0.2%
EBITDA
EBIT
-25.2%
EPS
-26.2%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
-10.6%
EBITDA
+9.2%
EBIT
+7.9%
Net income
+6.6%
EPS
+5.6%
Free cash flow

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026